Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials

• by Melinda J. Gooderham, H. Chih-ho Hong, Charles Lynde, Yvette Miller-Monthrope, Vimal H. Prajapati, Julien Ringuet, Irina Turchin, Jensen Yeung, Kim A. Papp

• July 14, 2026

A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”

• by Matthias Augustin, April W. Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres

• June 26, 2026

Connected Health May Match In-Person AD Care

A randomized clinical trial found that a team-based connected health model achieved equivalent improvements in atopic dermatitis severity and symptoms compared with conventional in-person care over 12 months.

• by Andrea Surnit

• July 9, 2026

• 3 min

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis

• by Jonathan I. Silverberg, Eric L. Simpson, Saleem A. Farooqui, Gary Chan, Pinaki Biswas, Erman Güler

• May 20, 2026